Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Director | September 12, 2016 | September 14, 2016 |
| ARRAY BIOPHARMA INCARRY · Entity 155788 | VP, General Counsel | April 01, 2017 | April 06, 2017 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | General Counsel | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date September 12, 2016 · Filed September 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2026-09-12 | Direct | 12,300 |
Reported balance
After 2016-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-12 · Grant · Acquired 12,300 · Balance 12,300 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
ARRAY BIOPHARMA INC
Report date April 01, 2017 · Filed April 06, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,102 |
Reported balance
After 2017-04-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-04-01 · Tax withholding · Disposed 6,370 · Balance 40,102 F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2022 Filed Sep 8, 2022 20:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,730 | $1.93 | $9,128.90 |
DisclosureSEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001562180-22-006030 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,502 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005918 · primarydocument.xml · derivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,558 Underlying: Common Stock · 4,502 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,730 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005918 · primarydocument.xml · derivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,457 Underlying: Common Stock · 4,730 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 9,232 | $9.31 | $85,921.30 |
DisclosureSEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,502 | $0.71 | $3,196.42 |
DisclosureSEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,730 | $1.93 | $9,128.90 |
DisclosureSEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,046 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · derivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,187 Underlying: Common Stock · 1,046 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,046 | $8.54 | $8,927.82 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.44 to $8.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 1,046 | $1.93 | $2,018.78 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,502 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · derivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,060 Underlying: Common Stock · 4,502 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,684 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · derivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,233 Underlying: Common Stock · 3,275 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,186 | $8.35 | $68,328.54 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $8.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,502 | $0.71 | $3,196.42 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 3,684 | $1.93 | $7,110.12 |
DisclosureSEC source: 0001562180-22-005621 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Read SEC document |
| June 21, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,508 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · derivative · entry 11 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,562 Underlying: Common Stock · 13,508 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 21, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,570 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · derivative · entry 10 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,917 Underlying: Common Stock · 17,570 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 21, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 31,078 | $7.29 | $226,695.36 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.72 to $7.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,570 | $1.93 | $33,910.10 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 13,508 | $0.71 | $9,590.68 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,127 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,487 Underlying: Common Stock · 22,127 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 22,127 | $6.62 | $146,434.27 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 22,127 | $1.93 | $42,705.11 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,722 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · derivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,614 Underlying: Common Stock · 14,722 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 14,722 | $6.17 | $90,805.30 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:50 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 14,722 | $1.93 | $28,413.46 |
DisclosureSEC source: 0001562180-22-005251 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 585 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · derivative · entry 12 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,336 Underlying: Common Stock · 585 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,075 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · derivative · entry 11 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,070 Underlying: Common Stock · 18,075 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 18,075 | $6.11 | $110,445.48 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 585 | $6.11 | $3,574.58 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,075 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 585 | $1.93 | $1,129.05 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 18,075 | $0.71 | $12,833.25 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,628 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · derivative · entry 10 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,145 Underlying: Common Stock · 3,628 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,628 | $6.02 | $21,854.71 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 3,628 | $0.71 | $2,575.88 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,093 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,773 Underlying: Common Stock · 4,093 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,093 | $6.01 | $24,581.74 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 22:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,093 | $0.71 | $2,906.03 |
DisclosureSEC source: 0001562180-22-005126 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,125 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,866 Underlying: Common Stock · 7,125 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,125 | $6.05 | $43,119.79 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,125 | $0.71 | $5,058.75 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,615 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · derivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,991 Underlying: Common Stock · 7,615 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,615 | $6.49 | $49,396.98 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.39 to $6.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,615 | $0.71 | $5,406.65 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,566 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · derivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,606 Underlying: Common Stock · 12,566 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 12,566 | $6.63 | $83,361.59 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.44 to $6.73, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 22:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 12,566 | $0.71 | $8,921.86 |
DisclosureSEC source: 0001562180-22-005053 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,150 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 12 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,172 Underlying: Common Stock · 17,150 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 973 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · derivative · entry 11 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,921 Underlying: Common Stock · 973 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 17,150 | $6.61 | $113,275.75 |
DisclosureSEC source: 0001562180-22-004887 · primarydocument.xml · nonDerivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.